Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV

Slides:



Advertisements
Similar presentations
Solange Arazi Caillaud. MD Emiliano Bissio. MD María Ester Lázaro. MD.
Advertisements

ARV failure and resistance for the paediatrician
HIV and its lifecycle Sources: Wikipedia, HIV is a retrovirus (enveloped viruses possessing an RNA genome,
Slide #1 HIV Entry Inhibitors Trip Gulick, MD, MPH Director, Cornell HIV Clinical Trials Unit Associate Professor of Medicine Weill Medical College of.
Pre Test !!!!!!. How many classes of HIV meds are currently available?
The gp41 fragment (purple) consists of a cytoplasmic tail and a hydrophobic membrane-spanning domain and is joined with the larger gp120 component (blue.
ANTIRETROVIRAL THERAPY Dr. Samuel Mwaniki (BPharm., MSc TID, UoN) University of Nairobi ISO 9001: Certified
 After completing this session the participant should be able to:  Discuss the goals of HIV treatment.  Understand when resistance testing should be.
HIV Care 2010: The 3 rd Revolution in HIV treatment Chris Farnitano, MD Noon Conference February 11, 2010.
HIV Lifecycle and Mechanisms of Antiretroviral Therapy
Dr Emmanuel Nsutebu Consultant Infectious Diseases Physician Tropical and Infectious Diseases Unit Royal Liverpool Hospital HIV “Myths, controversies and.
HIV and AIDS Human Immunodeficiency Virus (HIV) is the virus that causes Acquired Immunodeficiency Syndrome (AIDS).
HIV Structure, Lifecycle, and Replication
HIV = Human Immunodeficiency Virus
Combination of Drugs and Drug-Resistant Reverse Transcriptase Results in a Multiplicative Increase of Human Immunodeficiency Virus Type 1 Mutant Frequencies.
ANTIRETROVIRAL RESISTANCE Jennifer Fulcher, MD, PhD.
Antivirals for HIV Yasir Waheed, PhD. Some HIV Facts HIV – the Human Immunodeficiency Virus is the retrovirus that causes AIDS HIV belongs to the retrovirus.
HIV and AIDS Global: 40M HIV positive 25M AIDS deaths from ‘80 (60% sub-Saharan Africa) 80+% male Canada:63K HIV positive 16K AIDS deaths since 1980 (83%
HIV Therapy Experience is the Best Teacher David K. Stein, M.D. Director, Adult HIV Research Activities Jacobi Medical Center Associate Professor of Clinical.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 93 Antiviral Agents II: Drugs for HIV Infection and Related.
Failure Therapy VIRAL RESITANCE ADHERENCE!!!!!!!!!!! DRUG INTERACTION.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
© IAS–USA Johnson VA et al. Top Antivir Med. 2011;19(4): Updates, user notes, and references available at Mutations in the.
Anti-HIV Drugs Melissa Morgan Medicinal Chemistry November 23, 2004.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display The Steps in HIV Replication Slide number 1 (1) Viral.
Why African Americans Must Understand and Participate in Clinical Trials and Vaccines Virginia A. Caine, M.D. Associate Professor of Medicine Division.
Acquired Immunodeficiency Syndrome AIDS
HIV Life Cycle Step 1: Fusion Step 2: Transcription reverse transcriptase Step 3: Integration Step 4: Cleavage Step 5: Packaging and Budding HIV.
HIV: WHAT IS NEW? DR NYA EBAMA, M.D. LOWCOUNTRY INFECTIOUS DISEASES, PA CARETEAM PLUS, INC SEPTEMBER 18, 2015.
MedChem 401~ Retroviridae
Antiretroviral targets in the viral life cycle Viral Replication and Drug targets.
Basics of Human Immunodeficiency Virus (HIV) Brian Rybarczyk, PhD University of North Carolina- Chapel Hill.
Immune reconstitution Anjie Zhen, PhD
© IAS–USA Johnson VA et al. Top Antivir Med. 2013;21(1):4-12. Updates, user notes, and references available at Mutations in the Reverse.
Virology – Antivirals 2 JU- 2 nd Year Medical Students By Dr Hamed AlZoubi – Microbiology and Immunology Department – Mutah University. MBBS (J.U.S.T)
Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 94 Antiviral Agents II: Drugs for HIV Infection and.
19.09 Replication of HIV Slide number: 1
Antiretroviral Therapy (ART)
Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.
Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.
AIDS Chien-Ming Li MD, Ph.D.
ART 101 Successful HIV treatment usually consists of at least three drugs from two different “classes” of ARV drugs There are now six classes of ARV drugs:
Sofosbuvir-Velpatasvir in HIV-HCV Coinfected Patients ASTRAL-5
Principles of Pharmacology The Pathophysiologic Basis of Drug Therapy
Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses 
Giới thiệu về điều trị ARV
Human Health and Disease
Chapter 17a HIV infection and AIDS.
Comparison of current lowest global price vs estimated generic price, for medicines for diseases with large international treatment programmes. Comparison.
Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.
Antiviral Drugs Chapter 45.
The Influenza Virus Enigma
School of Pharmacy, University of Nizwa
Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.
Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and.
Combating Susceptibility to Drug Resistance
Replication life cycle of HIV and sites of antiretroviral drug action.
Forecasting for ARVs medicines
F. Canducci, B. Barda, E. Ceresola, V. Spagnuolo, M. Sampaolo, E
Volume 42, Issue 3, Pages (March 2005)
Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response.
Antiretroviral therapy and its complications
Terminology HIV AIDS Acquired Human Immune Immunodeficiency Deficiency
Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection  Lin Shen, MD, Robert F. Siliciano,
Antiviral chemotherapy
Figure 1. Rate of PDR in infants according to ARV exposure
Hematopoietic-Stem-Cell-Based Gene Therapy for HIV Disease
Combating Susceptibility to Drug Resistance
ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE
Presentation transcript:

Outwitting Evolution: Fighting Drug-Resistant TB, Malaria, and HIV Daniel E. Goldberg, Robert F. Siliciano, William R. Jacobs  Cell  Volume 148, Issue 6, Pages 1271-1283 (March 2012) DOI: 10.1016/j.cell.2012.02.021 Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 1 Antitubercular Drugs and Their Targets Standard “short-course” tuberculosis chemotherapy consists of 2 months of treatment with rifampicin, isoniazid, pyrazinamide, and ethambutol followed by four months on rifampicin and isoniazid. The targets of each member of the first-line quartet have been identified except for pyrazinamide, whose mechanism remains controversial. Drugs such as isoniazid, rifampicin, and the fluoroquinolones require active bacterial replication for activity, whereas pyrazinamide, nitroimidazoles, and TMC207 may be active against dormant bacilli. Cell 2012 148, 1271-1283DOI: (10.1016/j.cell.2012.02.021) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 2 Plasmodium Life Cycle Depicted are different stages. Red, intraerythrocytic stages; yellow, mosquito stages; brown, liver stages. PM/SX, pyrimethamine/sulphadoxine; ATOV/PG, atovaquone/proguanil; CQ/Q, 4-aminoquinolines like chloroquine and quinine and related compounds; ART, artemesinin and related compounds; TCN, tetracyclines; PQ, primaquine. Cell 2012 148, 1271-1283DOI: (10.1016/j.cell.2012.02.021) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 3 HIV-1 Life Cycle HIV-1 attaches to CD4 via envelope protein spikes on the surface of the virion. The CD4 interaction triggers a conformational change in the envelope protein that allows binding to a chemokine receptor, CCR5 or CXCR4. This is followed by further rearrangements of the envelope proteins that mediate fusion of the viral envelope and the cell membrane. The genomic viral RNA is then copied by RT to give double-stranded viral DNA that can be inserted into host cell DNA by integrase. Following transcription and translation, viral proteins and genomic viral RNA assemble into virions. During or shortly after release from the virus-producing cell, viral polyproteins are cleaved by HIV-1 protease into functional units, allowing infection of additional cells. Entry can be blocked by the chemokine receptor antagonist (CRA) maraviroc (MVC) or by the fusion inhibitor enfuvirtide (ENF). Reverse transcription is blocked by the NRTIs lamivudine (3TC), abacavir (ABC), zidovudine (AZT), stavudine (d4T), didanosine (DDI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) and by the NNRTIs efavirenz (EFV), nevirapine (NVP), etravirine (ETR), and rilpivirine (RPV). Integration is blocked by the integrase strand transfer inhibitors raltegravir (RAL) and elvitegravir (ELV). Virus maturation is blocked by the PIs amprenavir (APV), atazanavir (ATV), darunavir (DRV), indinavir (IDV), lopinavir (LPV), nelfinavir (NFV), saquinavir (SQV), and tipranavir (TPV). Cell 2012 148, 1271-1283DOI: (10.1016/j.cell.2012.02.021) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 4 Dose-Response Curves for Antiretroviral Drugs (A) Standard dose-response curve for a hypothetical antiretroviral drug. The fraction of infection events unaffected (fu) by the drug is plotted as a function of the log of the drug concentration (log D) for wild-type (WT) virus and a resistant mutant (mut). In this example, the IC50 for wild-type virus is 0.01 μM, and the clinical concentration range is 1–10 μM (pink shaded box). The slope of the dose response curve is 1. The resistance mutation is assumed to increase the IC50 by 100-fold without affecting the slope. The dotted lines indicate the IC50 values for wild-type and mutant viruses. (B) Dose-response curve for the viruses shown in (A) with the reproductive ratio R0 as a measure of infection. The resistance mutation is assumed to cause a 50% decrease in fitness. The dotted lines indicate the IC50 values for wild-type and mutant viruses. The gray line indicates an R0 value of 1. (C) Log-log plot of the dose-response curve shown in (B). The gray line indicates an R0 value of 1. (D) Effect of slope. Log-log plot of the dose-response curves for two drugs with the same IC50 (0.01 μM) and m values of 1 (blue curve) and 3.5 (green curve). Note that the y axis scale is expanded to capture the profound inhibitory effects achieved with a high slope value. The gray line indicates an R0 value of 1. (E) Effect of a single resistance mutation on inhibition by drug with high m. The drug is assumed to have an IC50 of 0.01 uM and a slope of 3.5. A resistance mutations increases the IC50 by 3-fold, reduces the slope by one-third, and decreases fitness in the absence of drug by one-half. Nevertheless, R0 for the mutant virus remains well below 1 throughout the clinical concentration range. (F) Changes in slope can affect resistance. In this example, a drug inhibits both WT and mutant virus with the same IC50 (0.1 μM). The mutation causes a 50% reduction in fitness but also reduces the slope from 1 to 0.5. Because there is no change in the IC50, standard methods of analysis would not classify the relevant mutation as a resistance mutation. However, in the clinical concentration range, the mutation does cause resistance due to the change in slope. Cell 2012 148, 1271-1283DOI: (10.1016/j.cell.2012.02.021) Copyright © 2012 Elsevier Inc. Terms and Conditions